[EN] NOVEL 1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS<br/>[FR] NOUVEAUX 1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES UTILISÉS EN TANT QU'AGONISTES M1
申请人:LUNDBECK & CO AS H
公开号:WO2009124883A1
公开(公告)日:2009-10-15
The present invention relates to novel MI agonistic compounds of the present invention. wherein R1 and R3 are idenpendently selected from H, cyano, halogen, such as F or C1, C1-6 alkoxy, such as methoxy, or C1-6 alkyI, such as methyl R2 is selected from H and halogen, such as F or C1; Y and Y' are individually selected from C1-3 alkyl, or Y and Y' together with the carbon atom to which they are attached, form a C3-7 cyctoalkyl group; and wherein each C1-3 alkyl and C3-7 cycloalkyl group may be optionally substituted with one or two substituents Z; Z is selected from hydrogen, C1-3 alkyl and halogen, such as F or C1; and their use in the treatment of cognitive impairment associated 1 a. w ith schizophrenia and in the treatment of other diseases mediated b> the muscarinic MI receptor
本发明涉及本发明的新型MI激动剂化合物。其中,R1和R3分别选自H、氰基、卤素(如F或Cl)、C1-6烷氧基(如甲氧基)或C1-6烷基(如甲基);R2选自H和卤素(如F或Cl);Y和Y'分别选自C1-3烷基,或者Y和Y'与它们附着的碳原子一起形成C3-7环烷基;每个C1-3烷基和C3-7环烷基可以选择地用一个或两个取代基Z取代;Z选自氢、C1-3烷基和卤素(如F或Cl);以及它们在治疗与精神分裂症相关的认知障碍以及治疗其他通过肌动蛋白MI受体介导的疾病中的应用。